TY - JOUR T1 - Late-breaking abstract: Non specific IgG replacement in lung transplantation recipients with low IgG plasma levels: Effects on survival and bronchiolitis obliterans syndrome occurrence JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - 219 AU - Christophe Pison AU - Marion France AU - Hubert Roth AU - Chrystel Saint Raymond AU - Johanna Claustre AU - Boubou Camara AU - Sébastien Quétant Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/219.abstract N2 - After lung transplantation, IgG plasma levels < 6 gr/L are recorded in more than 50% of cases resulting in adverse events (JHLT 2001;71:242; Transplantation 2005;79:1723). We conducted an open study with non specific IgG, Tegelines® in all patients with IgG plasma < 6 g/L post transplantation since 1991 in 59 out of 119 consecutive recipients who survived more than 3 months in Grenoble. Both groups had similar donor and recipient characteristics and events during a mean follow-up of 4.14±3.4 years except for a shorter duration of ventilation in donors, a longer first hospitalization stay and more acute rejection/TBB performed 0.32±1.2 (vs 0.11±0.18) in non-substituted group. IgG substitution started 4.5 [0-76] and lasted 5 [0-115] months, mean cumulative doses were 53±48 gr. In multivariate Cox regression model, IgG substitution conferred a net benefit in terms of survival at 5 years HR: 0.40 [0.18-0.88] 95%CI, p:0.022 taking in account age of recipients and donors, annualized number of treated infection and rejection episodes, and BOS free survival at 5 years HR: 0.50 [0.25-1.03] 95%CI, p:0.06 taking in account age of recipients and donors, type IC vs EC preservation solution, use of cardiopulmonary by-pass, annualized number of treated infection and rejection episodes. We conclude that replacement therapy with non specific IgG in lung transplant recipients with low IgG plasma levels resulted in a better survival and BOS free survival at 5 years post-transplantation as compared to non-substituted group. Limitation: non randomized design. A prospective controlled multicentre study is warranted. Funds from LFB, France. ER -